ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical company focused on advancing cancer care through the development of alpha radioligand therapies (ARTs). Founded in 2021, the company aims to create targeted cancer treatments by combining alpha-emitting isotopes with ligands that target specific tumor markers. ARTBIO's approach integrates a deep understanding of cancer biology with the infrastructure needed for designing, manufacturing, and distributing these therapies. The company's lead program, AB001, is being developed for prostate cancer treatment. ARTBIO is also innovating with its Pb-212 isolation technology, *AlphaDirect TM*, to enhance the production and distribution of alpha-emitting isotopes. With significant funding from partners like F-Prime Capital and Omega Funds, ARTBIO is building a comprehensive ecosystem to ensure effective delivery of its therapies to eligible patients, emphasizing a patient-centric approach in its mission to improve cancer treatment outcomes.

Research Cambridge, United States ~32 employees Private ยท Series A

Work at ARTBIO in HR or recruiting? Claim this page

Employees
32
+14.3% in the 3 months to Sep 2026
Revenue / employee
$55.5K
Revenue ~$1.8M
Total funding
$113M
Last round Series A, Dec 2023
12-month attrition
8.1%
H1B sponsor
NA
Open jobs
2
Last 30 days

Headcount trend

ARTBIO went from 14 employees in Oct 2024 to 32 in Sep 2026. Apr to Sep 2026: 5 people joined, 2 left.

Funding rounds

Total funding$113M
Funding rounds2
Investors2
DateRoundMoney raisedNo.Investors
Dec 2023Series A$90M2
Jun 2023Seed$23M1

Org structure

Headcount by department

Other18
Operations12
Finance2

Hiring now

ARTBIO FAQ

How many employees does ARTBIO have?

ARTBIO has about 32 employees, up 14.3% over the 3 months to Sep 2026.

What is ARTBIO's revenue per employee?

ARTBIO makes about $56K in revenue per employee, based on $1.78M annual revenue and 32 employees.

How much funding has ARTBIO raised?

ARTBIO has raised $113M in total funding; its latest round was Series A in Dec 2023.

Data from Company Prospectus, DOL LCA disclosures, WARN notices and 6figr salary profiles.